PD-L1 IHC 22C3 pharmDx for Cervical Cancer
In cervical cancer, PD-L1 testing with PD-L1 IHC 22C3 pharmDx (SK006) can help identify patients for treatment with KEYTRUDA1,2
- Globally, cervical cancer is the fourth most common cancer among women,3 and approximately 30,447 new cases were diagnosed in Europe in 20204
- PD-L1 testing provides a direct assessment of PD-L1 expression, which is a biomarker for response to anti-PD-L1 therapy in cervical cancer1,2
- In the KEYNOTE-826 clinical trial, PD-L1 IHC 22C3 pharmDx was used to assess PD?L1 expression in patients with persistent, recurrent, or metastatic cervical cancer who have not received prior systemic therapy*1,2
* Review the PD-L1 IHC 22C3 pharmDx Instructions for Use for more information regarding the KEYNOTE clinical trials
PD-L1 IHC 22C3 pharmDx was the only PD-L1 assay used in the KEYTRUDA KEYNOTE-826 clinical trial in cervical cancer1,2
PD-L1 IHC 22C3 pharmDx is CE-IVD–marked as the clinical trial?proven companion diagnostic for KEYTRUDA1
† Chemotherapy: paclitaxel and cisplatin or paclitaxel and carboplatin
‡ At the pre-defined study endpoint, the median OS of the KEYTRUDA arm in the CPS ≥ 1 population was not reached: meaning, more than 50% of treated patients were still alive
§ Hazard Ratio, 0.64; 95% Confidence Interval, 0.50–0.81
¶ Hazard Ratio, 0.62; 95% Confidence Interval, 0.50–0.77
Refer to the Cervical Cancer Interpretation Manual to review validated scoring guidelines that can aid in the identification of cervical cancer patients for treatment with KEYTRUDA
When confidence in a PD-L1 test is critical, the ONE you choose is crucial
- The ONE PD-L1 assay used in KEYTRUDA clinical trials1,2
- The ONE PD-L1 assay first launched with KEYTRUDA in every indication that requires PD-L1 testing1,2
- The ONE PD-L1 assay trusted worldwide to test hundreds of thousands of patients for KEYTRUDA5
References: 1. PD-L1 IHC 22C3 pharmDx [Instructions for Use]. Santa Clara, CA: Agilent Technologies, Inc.; 2022. 2. Keytruda [Summary of Product Characteristics]. European Medicines Agency; 2022. 3. World Health Organization. Cervical cancer, Key facts. //www.who.int/news-room/fact-sheets/detail/cervical-cancer (accessed April 15, 2022). 4. European Commission. Cervical cancer burden in EU-27. //ecis.jrc.ec.europa.eu/pdf/factsheets/cervical_cancer_en-Nov_2021.pdf (accessed April 15, 2022). 5. Data on file. Agilent Technologies, Inc.
For countries outside of the European Union, see the local KEYTRUDA product label for approved indications and expression cutoff values to guide therapy. D70833_01